Key Highlights

  • Pluri Inc. (NASDAQ:PLUR) traded at USD 1.03, down 8.04%, in pre-market trading on Tuesday, October 27, 2026. No company-specific announcement dated on or just before that day accompanied the move, which appears consistent with thin liquidity.
  • For the fiscal year ended June 30, 2026, the company reported cash, short-term deposits and restricted cash of USD 8.851 million, and management stated that resources cover operating obligations for less than three months from issuance.
  • The registered direct offering announced on Thursday, August 27, 2026 sold 2.23 million shares at USD 1.50 with warrants at USD 1.65, raising about USD 3.3 million gross for working capital and general corporate purposes.
  • A EUR 20 million European Investment Bank loan fell due on June 1, 2026 and remains outstanding. Pre-market prices are thinly traded and can change before the open at 9:30 a.m. ET on Tuesday, October 27, 2026.

The Pre-Market Move and Its Catalyst

Pluri Inc. (NASDAQ:PLUR), a biotechnology company that runs a three-dimensional cell expansion platform across cell therapy, contract manufacturing and food technology, traded at USD 1.03 in the pre-market snapshot of Tuesday, October 27, 2026, a decline of 8.04%. That implies a prior close of about USD 1.12, from simple arithmetic on the two published figures. No company-specific announcement dated on or just before Tuesday, October 27, 2026 accompanied the move. The decline appears consistent with thin pre-market liquidity, in which a small number of orders can shift the last price by several points, and with pressure on a share price now below the USD 1.50 level of the company's August financing.

How the Latest Results Frame the Move

The annual report on Form 10-K for the fiscal year ended June 30, 2026 shows cash, short-term deposits and restricted cash of USD 8.851 million. Management stated that existing resources cover operating obligations for a period of less than three months from the date the statements were issued, and the auditor included a going concern paragraph. The European Investment Bank loan of EUR 20 million carries 4% interest, fell due on June 1, 2026 and had about EUR 4.1 million of accrued interest at year end. On Monday, August 17, 2026 the bank approved a proposed sale of the loan to a third party, and the company may seek to convert it into equity. Pluri Inc. (NASDAQ:PLUR) had 12,344,736 shares outstanding on Wednesday, September 9, 2026.

Risks and What to Watch

The bull reading rests on the company's operating assets: the PluriCDMO unit received ISO 13485:2016 certification in August 2026, and the Phase I PROTO study of PLX-PAD in knee osteoarthritis began in January 2026. The bear reading rests on funding. Cash covers less than three months and the loan is past due, while the registered direct offering of Thursday, August 27, 2026 was priced at USD 1.50, above the present quote, with warrants exercisable at USD 1.65. Named risks are dilution through further equity or a loan conversion, Nasdaq listing compliance, because the company must regain the USD 35 million minimum market value of listed securities or meet an alternative standard, and thin liquidity. Investors should watch any loan restructuring, any further financing and the Federal Reserve decision on Wednesday, October 28, 2026.

Where Things Stand

The answer is that Pluri Inc. (NASDAQ:PLUR) fell in a pre-market session without a dated company announcement, and the move appears consistent with thin liquidity and a funding profile that leaves little margin. The key number is USD 8.851 million of cash and deposits at June 30, 2026, set against a management statement that resources last less than three months. The next catalysts are any update on the European Investment Bank loan, any new financing or listing notice and the Federal Reserve decision on Wednesday, October 28, 2026. Pre-market prices are snapshots and can change before the open, and this is not investment advice.